Anthera Pharmaceuticals, Inc. (Anthera) is a development-stage, biopharmaceutical Company focused on developing and commercializing products to treat diseases associated with inflammation. As of December 31, 2011, the Company had one Phase-II clinical program, blisibimod. Two of its product candidates, varespladib and varespladib sodium, are designed to inhibit an enzyme target known as secretory phospholipase A2 (sPLA2). sPLA2 have been implicated in a range of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome associated with sickle cell disease, as well as in chronic diseases, including stable coronary artery disease (CAD). In addition, blisibimod targets B-lymphocyte stimulator (BLyS), also known as B-cell Activating Factor (BAFF), which has been associated with a range of B-cell mediated autoimmune diseases.